EUVIMEDEUVIMED entdecken
Multizentrische Studie

1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System

Raj Makkar, Moody M Makar, Sabah Skaf, Scott Chadderdon, Howard K Song, Charles J Davidson, S Chris Malaisrie, D Scott Lim, Dale E Fowler, Jacob M Mishell, Ivy A Ku, Tarun Chakravarty und 8 weitere

JACC: Cardiovascular Interventions · 2025-09 · 18 (18) · 2256-2266

DOI: 10.1016/j.jcin.2025.08.009 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-09. Verfasst von Raj Makkar und 19 weiteren Autor:innen. Beteiligte Einrichtung: Cedars-Sinai Medical Center, Los Angeles, California, USA. Electronic address: raj.makkar@cshs.org. Hauptthemen laut MEDLINE: Femoral Artery, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Mitral Valve. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Transcatheter mitral valve replacement (TMVR) may benefit patients at high surgical risk with mitral regurgitation (MR). OBJECTIVES: The authors report 30-day and 1-year outcomes of transfemoral TMVR. METHODS: The MISCEND (Edwards Eos Mitral Valve Replacement: Investigation of Safety and Performance After Mitral Valve Replacement With Transcatheter Device) study is a prospective, single-arm, multicenter evaluation of the Eos transcatheter mitral valve replacement system for clinically significant, symptomatic MR. Performance and safety endpoints included device success, procedural success, 30-day rate of MR ≤1+ and 30-day composite major adverse event rate. Additional clinical, echocardiographic, functional, and quality-of-life outcomes were assessed through 1 year. RESULTS: Sixty patients (median age 79.5 years, Society of Thoracic Surgeons score 5.2%, 40% men, 43.3% with functional MR) were enrolled. Device and procedural success rates were 100.0%. The 30-day composite major adverse event rate was 43.3%, including all-cause mortality (5.0%), all-cause hospitalization (21.7%), nonelective mitral valve reintervention (1.7%), severe bleeding (28.3%), renal complication requiring unplanned dialysis or renal replacement therapy (5.0%), and major cardiac structural complication (8.3%). The rate of MR ≤1+ was 98.1% at 30 days and 100.0% at 1 year, with none/trace MR in 63.0% and 78.4% of patients, respectively. One-year outcomes showed significant improvements in 6-minute walk distance (40.5 m; 95% CI: 13.8-97.2 m; P = 0.003) and Kansas City Cardiomyopathy Questionnaire overall score (17.7 points; 95% CI: 11.2-27.3 points; P < 0.01), with 86.8% of patients in NYHA functional class I/II. Rates of mortality and left ventricular pseudoaneurysm were 20.3% and 10.0%, respectively. CONCLUSIONS: 1-year MISCEND results demonstrate the feasibility of TMVR with the Eos system. Although safety concerns related to left ventricular pseudoaneurysm resulted in the cessation of study enrollment, learnings will inform future therapy development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Femoral ArteryHeart Valve ProsthesisHeart Valve Prosthesis ImplantationMitral ValveMitral Valve InsufficiencyAgedAged, 80 and overFemaleHumansMaleCardiac CatheterizationCatheterization, PeripheralProspective StudiesProsthesis DesignPuncturesQuality of LifeRecovery of FunctionRisk FactorsTime FactorsTreatment OutcomeUnited States

Stichwörter der Autor:innen

degenerative mitral regurgitationearly feasibility studyfirst-in-humanfunctional mitral regurgitationtranscatheter mitral valve intervention

Autor:innen und Institutionen

  • Cedars-Sinai Medical Center, Los Angeles, California, USA. Electronic address: raj.makkar@cshs.org.
  • Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Oregon Health & Science University, Portland, Oregon, USA.
  • Northwestern University, Chicago, Illinois, USA.
  • University of Virginia Health System Hospital, Charlottesville, Virginia, USA.
  • Kaiser Permanente San Francisco Medical Center, San Francisco, California, USA.

Zitieren

APA

Makkar, R., Makar, M. M., Skaf, S., Chadderdon, S., Song, H. K., Davidson, C. J., Malaisrie, S. C., Lim, D. S., Fowler, D. E., Mishell, J. M., Ku, I. A., Chakravarty, T., Szeto, W. Y., Herrmann, H. C., Smith, R. L., Szerlip, M., Koulogiannis, K. P., Marcoff, L., Zahr, F., & MISCEND Study Investigators (2025). 1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System. JACC: Cardiovascular Interventions, 18(18), 2256-2266. https://doi.org/10.1016/j.jcin.2025.08.009

Vancouver

Makkar R, Makar MM, Skaf S, Chadderdon S, Song HK, Davidson CJ, et al. 1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System. JACC: Cardiovascular Interventions. 2025;18(18):2256-2266. doi:10.1016/j.jcin.2025.08.009

BibTeX
@article{Makkar2025,
  author = {Makkar, Raj and Makar, Moody M and Skaf, Sabah and Chadderdon, Scott and Song, Howard K and Davidson, Charles J and Malaisrie, S Chris and Lim, D Scott and Fowler, Dale E and Mishell, Jacob M and Ku, Ivy A and Chakravarty, Tarun and Szeto, Wilson Y and Herrmann, Howard C and Smith, Robert L and Szerlip, Molly and Koulogiannis, Konstantinos P and Marcoff, Leo and Zahr, Firas and MISCEND Study Investigators, MISCEND Study Investigators},
  title = {1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {18},
  pages = {2256--2266},
  doi = {10.1016/j.jcin.2025.08.009}
}
Kostenlos starten →